Farsijani, Safi and Shirazi Beheshtiha (2023), Archives of Razi Institute. Diagnostic comparison in 30 cats. Reports 100 per cent sensitivity and 81.8 per cent specificity for the specific modulation frequency test. The reference standard included the index test itself, which is a design flaw.
Krzysztof, Strus and Nabagło (2020), Research Square preprint. In vitro test on bacterial and fungal strains. Reports no significant reduction in pathogen counts compared with controls. Not peer reviewed.
Cosentino and colleagues, University of Insubria (2026), bioRxiv preprint. In vitro, blinded, active device against a mock device, cell cultures. Reports the active QDOME device reduced hydrogen peroxide induced cell death. Not yet peer reviewed.
Cabıoğlu and colleagues (2022), Bulletin of Experimental Biology and Medicine. Animal study, chronic mild stress model in mice. Reports shorter immobility in forced swim and tail suspension tests after longer bioresonance exposure. The authors call for replication.
Del Giudice and colleagues (2015), Current Topics in Medicinal Chemistry. Labelled a phase II clinical trial; sample size not stated in the abstract. Reports cytokine reductions and outcomes the authors call comparable to narrow-band UVB, using a “WHITE Holographic Bioresonance” method.
Genç and colleagues (2024), Anadolu Tıbbı Dergisi, Turkish. Case report, two patients in breast cancer follow-up. Reports SF-36 quality of life improvement after one month of BICOM Optima sessions. Two cases, no comparison group.
Barassi and colleagues (2024), Medicina (Kaunas). Pilot observational study, before and after, 20 patients. Reports changes in SF-36, Bristol stool scale and faecal calprotectin after eight sessions. The device is an extremely low frequency electromagnetic field system, not BICOM or MORA.
Dur and Şensoy (2026), International Journal of Traditional and Complementary Medicine Research. Prospective single-arm cohort, 50 smokers, carbon monoxide verified at one and three months. Reports 28 per cent continuous abstinence at twelve months; low mood and sleep problems predicted relapse.
Marakoğlu and colleagues (2024), İstanbul Medical Journal. Retrospective cohort from a smoking cessation clinic, 1,272 patients. Reports MORA bioresonance was the most chosen method, and no significant difference in quit success between methods (p=0.132).
Muresan and colleagues (2022), Experimental and Therapeutic Medicine. Two-group comparison against SSRI monotherapy, not randomised. Reports mean Hamilton score change of 3.1 with bioresonance against 2.2 with SSRI. Overlaps the group’s 2021 dataset.
